Long-Term Follow-up for 1,064-nm Nanosecond and Picosecond Laser Treatment of Acquired Bilateral Nevus of Ota-Like Macules

Phothong, Weeranut; Manuskiatti, Woraphong; Wongdama, Supisara; Gulfan, Ma Christina

doi:10.1097/dss.0000000000003542

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te possible reason for the better efcacy of the picosecond laser may be that PSAL fuence was high enough to generate sufcient photothermolysis to damage those dermal melanocytes in nevus of Ota, thus leading to more lesion clearance. On the other hand, the possible reasons for the better efcacy of LF-QSNY may be that the photothermal damage for the picosecond laser was relatively high that PIH had been raised and not fully recovered by three months, or the damaged melanocytes had not achieved full degradation at threemonth follow-up since further improvement had been noted by some clinicians at six months to one year after the last treatment [7,25]. Te results suggest that an initial test patch is necessary for subsequent treatment of nevus of Ota.…”

Section: Discussionmentioning

confidence: 99%

Low-Fluence Q-Switched Nd: YAG Laser (LF-QSNY) May Be a Better Choice for the Treatment of Early Nevus of Ota: A Prospective Self-Controlled Trial of LFQS and Picosecond Alexandrite Laser

Zhou,

Zhu,

Cen

et al. 2024

Dermatologic Therapy

View full text Add to dashboard Cite

Background. Low-fluence Q-switched Nd: YAG laser (LF-QSNY) and picosecond 755 nm alexandrite laser (PSAL) have shown superiority in the treatment of nevus of Ota (NO). Objective. To compare the efficacy and safety of PSAL and LF-QSNY in the treatment of NO. Methods. 15 patients randomly underwent split-lesion treatment of the two lasers within three months. The visual analogue scale (VAS) was used to evaluate the efficacy outcomes. The patient’s preferences, recurrence rate, and adverse events were also documented. Results. Fifteen patients with 34 lesions finished the trial. Lesions, operated with LF-QSNY and PSAL, reached VAS scores of 3.47 ± 0.67 and 3.51 ± 0.87, respectively (P>0.05). Most significant improvement in LF-QSNY was achieved after the first session (VAS = 1.84). One (6.67%) patient experienced a relapse on the PSAL side. Temporary hypopigmentation and hyperpigmentation mainly occurred on the PSAL side. Patients under five years demonstrated superior efficacy (3.81 ± 0.47 vs 3.08 ± 0.66, P=0.046) than those over with the treatment of LF-QSNY. Limitations. Limited sample and lack of objective evaluation. Conclusion. The difference between the LF-QSNY and PSAL in the treatment of NO was statistically insignificant, while LF-QSNY may be a better choice for the treatment of early NO. This trial is registered with ChiCTR1900022690.

show abstract

Section: Discussionmentioning

confidence: 99%

Low-Fluence Q-Switched Nd: YAG Laser (LF-QSNY) May Be a Better Choice for the Treatment of Early Nevus of Ota: A Prospective Self-Controlled Trial of LFQS and Picosecond Alexandrite Laser

Zhou,

Zhu,

Cen

et al. 2024

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Comparison of the efficacy and safety of a 730‐nm picosecond titanium sapphire laser and a 1064‐nm picosecond neodymium yttrium aluminum garnet laser for the treatment of acquired bilateral nevus of Ota‐like macules: A split‐face, evaluator‐blinded, randomized, and controlled pilot trial

Chen,

Wang,

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundThe picosecond neodymium yttrium aluminum garnet laser (PNYL) has been successfully used in treating acquired bilateral nevus of Ota‐like macules (ABNOM). The 730‐nm picosecond titanium sapphire laser (PTSL) is an emerging tool for pigmentary disorders. However, no studies have compared two different wavelengths of picosecond laser for the treatment of ABNOM.AimsTo compare the efficacy and safety of the 730‐nm PTSL with the 1064‐nm PNYL in the treatment of ABNOM.MethodsFifteen participants with ABNOM were randomized to undergo a single session of either the 730‐nm PTSL on one side of the face and 1064‐nm PNYL on the other side. Efficacy and safety assessments were performed by blinded visual evaluations at baseline, 12 weeks, and 24 weeks posttreatment. Participants' satisfaction and adverse effects were recorded.ResultsCompared to baseline, The 730‐nm PTSL‐treated side showed better improvement than that of the 1064‐nm PNYL‐treated side at 24 weeks posttreatment (1.67 ± 1.047 vs. 0.87 ± 0.640, p = 0.027). There were no significant differences in pain sensation and participants' satisfaction between the two laser treatments.ConclusionsThe 730‐nm PTSL is more effective than the 1064‐nm PNYL in the treatment of ABNOM.

show abstract

Long-Term Follow-up for 1,064-nm Nanosecond and Picosecond Laser Treatment of Acquired Bilateral Nevus of Ota-Like Macules

Cited by 2 publications

References 5 publications

Low-Fluence Q-Switched Nd: YAG Laser (LF-QSNY) May Be a Better Choice for the Treatment of Early Nevus of Ota: A Prospective Self-Controlled Trial of LFQS and Picosecond Alexandrite Laser

Low-Fluence Q-Switched Nd: YAG Laser (LF-QSNY) May Be a Better Choice for the Treatment of Early Nevus of Ota: A Prospective Self-Controlled Trial of LFQS and Picosecond Alexandrite Laser

Comparison of the efficacy and safety of a 730‐nm picosecond titanium sapphire laser and a 1064‐nm picosecond neodymium yttrium aluminum garnet laser for the treatment of acquired bilateral nevus of Ota‐like macules: A split‐face, evaluator‐blinded, randomized, and controlled pilot trial

Contact Info

Product

Resources

About